Cipla Ltd

Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015

09:34 PM, 20th Feb 2025

Company has received final approval from USFDA for NDA submitted for Nilotinib Capsules 50 150 and 200 mg on 19th February 2025